EX-10.1





 Certain confidential information contained in this document, marked by [**], has been
omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. 

Exhibit 10.1 
 EXCLUSIVE
LICENCE OF PATENTS AND RESULTS 
 BETWEEN THE UNDERSIGNED, SOPHIA GENETICS SA, a company duly incorporated in accordance with the laws
of Switzerland, under registration number CH-550.1.086.569-3 in the Commercial Register of the Canton of Vaud, domiciled at Rue du Centre 172, 1025 St-Sulpice, Switzerland, represented by [**], duly authorised for this purpose and hereinafter referred to as the “Company”; 

AND 
 COMUE NORMANDY UNIVERSITY, a national
public institution of a scientific, cultural and professional nature, [**], whose statute was approved by decree no. 2014-1673 of 29 December 2014, represented by its President, [**] hereinafter referred to as “Normandy
University”, acting in the name and on behalf of its Normandie Valorisation [Normandy Valuation] [**], hereinafter referred to as “Normandie Valorisation”; 

AND 
 INSERM TRANSFERT SA, Public Limited
Company with a Management Board and Supervisory Board, [**], with its registered offices at [**], [**], represented by [**], acting as delegate of the National Institute of Health and Medical Research, a public scientific and technological
establishment with its registered offices at [**], hereinafter referred to as “INSERM Transfert”; 
 THE HENRI BECQUEREL
CENTRE, ESPIC [Etablissement de Santé Privé d’Intérêt Collectif (Private Healthcare Facility of Collective Interest)] Cancer Centre, with its registered offices at [**], [**], represented by [**] (hereinafter
referred to as “CHB”), acting on behalf of [**], hereinafter referred to as “Laboratory 1”; 
 AND 

THE UNIVERSITY OF ROUEN NORMANDY, a national public institution of a scientific, cultural and professional nature, with its registered
offices at [**], [**], represented by [**] (hereinafter referred to as “UNIROUEN”), acting on behalf of [**] directed by [**], hereinafter referred to as “Laboratory 2”; 

The CH, INSERM Transfert and UNIROUEN are hereinafter referred to as the “Establishments”. The CHB, INSERM Transfert,
UNIROUEN, Normandie Université and the Company may each be referred to hereinafter individually as “Partner” and collectively as “Partners”. 

[**] 












 It is, however, specified that this delegation does not imply the transfer to INSERM
Transfert of property rights held or jointly held by INSERM. 
 For the execution of this Agreement, INSERM is not considered to be a third
party. 
 The CHB, INSERM Transfert and UNIROUEN mandate Normandy University via its Normandie Valorisation component to ensure the entire
management of this licence Agreement, in accordance with the stipulations of the mandate commitment between Normandy University and the Establishments. 

In accordance with this mandate, Normandy University is authorised to sign this Agreement in the name and on behalf of the Establishments.

 The Establishments, Normandy University and the Company are hereinafter referred to jointly as the “Parties” and
collectively as the “Party”. 
 WHEREAS, 

Within the framework of research carried out within the Laboratory, [**], 

The Establishments are the co-owners of [**]; 

Informal exchanges have already taken place between the Establishments and the Company. The list of elements made available by the
Establishments in this context is given in Appendix 1 (an integral part of this Agreement); and 
 The Company is interested in the
aforementioned patent applications and wishes to join forces with the Establishments to validate, through collaboration, the possibilities for developing and exploiting the technology covered by these patent applications; 

Consequently, the Establishments grant the Company an exclusive licence on the patents mentioned above under the terms and conditions defined
below. 
 CONSEQUENTLY, IT IS AGREED AS FOLLOWS: 

“Affiliates” refers to any legal entity that: 
  

	 	•	 	 directly or indirectly controls the Company; or 



 

	 	•	 	 comes under the same direct or indirect control as the Company; or 



 

	 	•	 	 is controlled directly or indirectly by the Company. 



  
 2 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 A legal entity is considered to be controlling another: 

 

	 	•	 	 when it directly or indirectly holds more than 50% (fifty percent) of the share capital of that legal entity or
holds more than 50% (fifty percent) of the voting rights of the shareholders or partners of that legal entity; or 


  

	 	•	 	 when it de facto directly or indirectly holds the decision-making power within this legal entity.



 The rights granted to the Affiliates under the terms of this Agreement are only applicable to legal entities that have
the status of Affiliate at the moment when these rights are exercised. If a legal entity loses the status of Affiliate during the term of this Agreement, the rights that legal entity acquired due to its status as an Affiliate shall expire
immediately, unless agreed in writing by the Establishments. Conversely, a legal entity that acquires Affiliate status shall also acquire the rights relating thereto. 

The list of Affiliates is given in Appendix 4, an integral part of this Agreement. 

“Agreement” means this Agreement, in its entirety, including its appendices and any amendments. 

“Business Partners” refers to entities that have a business relationship with the Company for the purpose of executing or
carrying out all or part of the development plan for the Products or allowing them to be used, in accordance with the conditions set out below. 

“Confidential Information” refers to any information transmitted by one of the Parties to the other under this
Agreement that relates to the Field of Use and is designated as confidential during its transmission by making reference in words to this confidentiality. Any confidential information transmitted orally must be confirmed in writing within [**] of
its transmission. 
 “Date(s) of First Provision” refers to the first time that the Company made the Products available to
a third party to the Agreement. The Date of First Provision will be effective on the day when the Company exceeds the most rapidly reached duration provided for in Section 4.05 of this Agreement. 

“Development Works” refers to all of the works and studies carried out directly by the Company on its own and/or jointly with
the Establishments in accordance with the development plan in Appendix 2 of the Agreement, including all of the works and studies that are necessary for the Company to develop and market the Products directly, or indirectly through its Affiliates.

 “Effective Date” refers to the last date on which this Agreement was signed by all the Parties. 

  
 3 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 “Field of Use” refers to acute myeloblastic and lymphoblastic leukemia (AML
and ALL) and chronic myeloid leukemia (CML). 
 “Industrial Property Fees” refers to the direct costs invoiced by the
industrial property firm(s) and by their foreign equivalents for the operations of filing, issuing and maintaining the Patent. Industrial Property Fees do not include any subsequent costs incurred in legal proceedings initiated by one and/or the
other of the Parties to defend the Patent. 
 “Patents” refers to: 

 

	 	•	 	 French patent no. [**] in the names of Establishments, and citing [**] as the inventors thereof.



  

	 	•	 	 the PCT application filed under [**] in the names of the Establishments, 



 

	 	•	 	 all rights resulting from these applications, including (i) all patents and patent applications with the
aforementioned French patent application claiming priority elsewhere in the world, (ii) the patents resulting from these applications and (iii) all divisional applications, applications for continuation in whole or in part, re-issues, the reviews, extensions and related rights, 


 A statement of the Patent
portfolio on the date of signature of this Agreement is attached in Appendix 2. 
 The Parties expressly understand that the distribution
and management of property rights relating to patent applications nos. [**] and [**] only concerns the Establishments and they cannot therefore, under any circumstance, dispute the conditions of the Patent’s industrial and commercial use from
which the Company would benefit. 
 An update to Appendix 1 will be carried out as the Agreement is completed. 

“Products” refers to the products that have been developed, manufactured or marketed and that could not be developed, used,
manufactured, marketed or implemented without infringing all or part of the Patent. In the case of returns provided for in Article 5 of this Agreement, the term Product is understood to be for a single patient, and the same applies for the duration
provided for in Section 4.05 of this Agreement. 
 “Result” refers to the results arising from the Patent, as well as
the technical and scientific knowledge acquired by Laboratories 1 & 2 while executing the various stages of the Patent and that may or may not be protected by an industrial property title. 

“Territory” refers to the countries covered by the Patent. 

“Valid Claim” refers to any claim in an application for a Patent or a Patent in force and not expired, which has not been
withdrawn, cancelled or found to be invalid or unenforceable, by a court or any other competent jurisdiction, by a final ruling and/or a judgement that cannot be appealed. 

  
 4 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Words in the plural may be understood in the singular, and vice versa. 

ARTICLE 1 
 PURPOSE,
TYPE AND SCOPE OF THE AGREEMENT 

Section 1.01. By means of this Agreement, the Establishments grant to the Company, to its Affiliates and to its Business Partners, which
accept, an exclusive license to the Patents, in order to develop, manufacture and sell Products in the Field of Use and in the Territory (hereinafter the “Licence”). The granting of this licence excludes any rights to sub-licence. 
 The Company shall not exploit the patents resulting from patent applications no. [**] and
no. [**] outside the Field and the Territory. 
 It is understood that the Establishments retain the right to use the Patents and Results
internally for research and teaching purposes, excluding any use for commercial purposes in the Field and in the Territory. 

Section 1.02. The Licence is only granted for Patents and does not extend to improvements made by one and/or the other of the
Establishments to the Patents, nor to countries other than those covered by the Territory. However, the UNIROUEN and the CHB acknowledge that they will make the Patent updates available to the Company in the Field and in the Territory. 

ARTICLE 2 
 DURATION

 The Licence comes into effect on the last date of signature by the Partners and, except in the event of early termination pursuant to the
provisions of Article 10 below, will remain in force for one (1) year from the last date of signature by the Partners. The licence will remain in force for the same duration as the rights attached to the Patent. 

ARTICLE 3 
 TRANSFER
OF THE LICENCE AGREEMENT 
 Section 3.01. This Agreement is concluded
intuitu personae. Consequently, the Agreement is personal, non-assignable and non-transferable. 

Section 3.02. In the event of a takeover, merger, absorption, sale or transfer of the Company or its activities, respectively, by, with
or to another legal entity, or any other transformation of the Company that may alter the intuitu personae character of this Agreement (hereinafter referred to as the “Event(s)”), Normandy University via Normandie
Valorisation, acting for and on behalf of the Establishments, and the new legal entity will sign exactly the same terms as for this Agreement. 

  
 5 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 An amendment to this Agreement between the Establishments, Normandy University and said
legal entity must be drawn up, simultaneously with any Event that takes place with the Company. 
 ARTICLE 4 

PRODUCT DEVELOPMENT – OPERATION 

Section 4.01. A development plan (hereinafter referred to as the “Development Plan”) expressing the conditions under
which the Company intends to carry out the Development Works, the provisional timetable for the execution of said Development Works, as well as the date planned for the first launch of the Products onto the market. The Development Plan is described
in Appendix 3 of this Licence. 
 The Company undertakes to inform Normandy University, via Normandie Valorisation, acting on behalf of the
Establishments, of any unforeseen event concerning the said Development Plan which could delay its execution by more than [**]. In such cases, the Company will propose an update of the updated Development Plan corresponding to the development
practices for the sector concerned and free from the technical and/or scientific constraints encountered at the origin of the said delay. 

The new Development Plan must be agreed by Normandy University via Normandie Valorisation, and said agreement may only be refused by Normandy
University via Normandie Valorisation if (1) the delay is caused by the financial or strategic decisions of the Company (such as the internal prioritisation of projects, an absence or delay in raising sufficient funds for the execution of the
Development Plan) or (2) if the Development Plan does not comply with the development practices of the sector concerned. The Company must provide proof that it has remedied said delay through said update to the Development Plan so as to favour
the development and marketing of the Products. 
 Section 4.02. The Company undertakes to keep Normandy University via Normandie
Valorisation, acting on behalf of the Establishments, informed of the progress of the development of the Products at least [**]. To this end, meetings will be organised at least [**]. These meetings may be held by telephone or by videoconference and
the Company will take written minutes of the same. Normandy University via Normandie Valorisation will then send these minutes to the Establishments for information purposes. The report will be used for calculating the invoice that the Company will
have to pay. 
 Section 4.03. The Company undertakes to use this Licence and to apply due diligence to develop, manufacture and sell
the Products in the Field of Use and in the Territory. If the Company does not use this Licence within [**] of its Effective Date, this Licence will henceforth become non-exclusive and the Establishments may
sign other Licences with third parties in the Field and in the Territory. 

  
 6 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Section 4.04. The quality control of the Products and any act relating to the same are
under the exclusive responsibility of the Company; the Establishments will in no way be required to lend their assistance. 

Section 4.05. The Company is granted the possibility, for a period of [**] from the last date of signature by the Partners or for [**],
the first of the two deadlines being taken into account, of making the Products available free of charge. 
 From the First Marketing Date,
the Company undertakes to provide and communicate to Normandy University via Normandie Valorisation, within [**] following the end of the Company’s annual financial year, an annual report justifying the use of Products. 

The Establishments may reduce the Territory and/or the Field of Use, by way of an amendment to this Agreement, if the Company has not marketed
nor implemented the steps necessary for the marketing of the Products in the Territory and/or in the Field within a reasonable time after the end of the development plan, or if the delay in the execution of the development plan exceeds [**]. These
steps are described in Appendix 3 attached to this Agreement, entitled “Development Plan”. 
 This reduction of the Territory
and/or the Field of the Licence will be the subject of an amendment to this Agreement specifying the new definition of the Territory and/or the Field as well as the effective date of the revision. 

Notwithstanding this reduction in the scope of the Territory and/or the Field, the other rights and obligations of the Parties provided for in
the Licence will continue as of right. 
 Section 4.06. The Company and/or its Affiliates and/or its Business Partners, without
prejudice to what is provided for in the following paragraph, are prohibited from using any of the following names for commercial promotion purposes: [**], or any trademark or distinctive sign belonging to any of the Establishments, or any
adaptation of the same, as well as the name of the inventors and any of the Establishments’ agents, without having received, prior to each use, the written consent of the Establishment(s) concerned and, if applicable, the natural person
concerned. 
 However, solely for the purpose of providing information concerning the origin of the Licence, the wording [**] must appear on
all Products, advertising materials, and technical or explanatory leaflets relating to the Products, provided that at least one Valid Claim exists for the Patent. It will be up to the Company and/or its Affiliates to ensure that this wording, due to
its form and the context in which it is placed, cannot be interpreted as any kind of guarantee given by the Establishments concerning the Products. 

  
 7 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Section 4.07. The Establishments shall not under any circumstances disclose the name of
the Company and/or the Affiliates in advertising or any other promotional material intended for the general or medical public and shall not use the name of any employee of the Company and/or Affiliates, nor any product trademark, service mark, trade
name or symbol belonging to the Company or Affiliates of the same, without the Company’s prior written consent (an email will suffice). 

The Establishments undertake not to use the name of the Company, or the name of its employees or of those in whose name it acts. 

Section 4.08. The Company hereby acknowledges that it has the expertise and competences required to use the Patents and Results and to
market the Products. 
 ARTICLE 5 

FINANCIAL TERMS 

Section 5.01. In return for this Licence, the Company and/or its Affiliates must pay Normandy University via Normandie Valorisation,
acting on behalf of the Establishments, the following amounts: 
  

	 	(a)	 Lump sums 


  

	 	•	 	 An initial sum of [**] excluding taxes ([**] excluding tax) on the last date of signature by all the Parties;



  

	 	(b)	 Royalties per analysis 



In return for the rights to use the Patent and the Results that the Establishments grant to the Company (and/or its Affiliates), the Company
will pay Normandy University annually via Normandie Valorisation the following on behalf of the Establishments: 
  

	 	•	 	 Under direct use: 



A royalty of [**] for each analysis [**]. 

The fees provided for in this article shall be payable for each country as long as there is a Valid Claim for a Patent in the country
concerned. 
  

	 	•	 	 Under indirect use: 



The same royalty rates will be applied if the Company markets the Products directly or indirectly via its subsidiaries and/or its Business
Partners. 

  
 8 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Section 5.02. Royalties on sales concluded in currencies other than the Euro will be
calculated based on the annual average of the exchange rate published by the Banque de France. 
 Section 5.03. In accordance with the
Mandate commitment signed by the Establishments, Normandy University via its Normandie Valorisation component will recover [**] of the amount due to the Establishments. 

Section 5.04. The minimum sale price of each Product by the Company and/or its Affiliates and/or its Business Partners is set at [**],
excluding taxes ([**] before tax). 
 ARTICLE 6 

MONITORING OF FEES 

Section 6.01. The Company will keep an accurate register of the number of Products that have been distributed under the Agreement [**].

 The elements of the register will be made available to Normandy University via Normandie Valorisation [**] per year, until the expiry
date of this Agreement extended by [**]. 
 This register will be closed on [**], and the Company will send Normandy University via
Normandie Valorisation, no later than [**] following the year concerned, a detailed statement of sales relating to the Products, broken down by country. 

This statement will show the number of analyses per patient, including the Products used during the period, as well as the related amount in
accordance with the fees per analysis provided for above. 
 This statement of commercial transactions will be sent to the following
address: [**]. 
 Section 6.02. The sums due by the Company and/or its Affiliates and/or its Business Partners in accordance with
Article 5 of this Agreement must be paid within [**] of [**] of issue of an invoice by Normandy University via Normandie Valorisation, acting on behalf of the Establishments, by bank transfer to the following EPSCP Normandy University account: 

Bank code: [**] 
 Counter Code
No. [**] 
 Account No. [**] 

IBAN code: [**] 
 SWIFT BIC: [**]


  
 9 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Section 6.03. Any sum not paid to Normandy University via Normandie Valorisation within
the aforementioned deadlines, due to a late payment, shall give rise to late payment interest calculated at the rate of [**] the legal interest rate in force. In addition, the Company will automatically owe Normandy University via Normandie
Valuation a lump-sum compensation for recovery costs of [**] excluding taxes ([**] excluding tax). 

Section 6.04. The sums owed by the Company to Normandy University via Normandie Valorisation, acting on behalf of the Establishments,
under this Agreement will be paid in euros. 
 Section 6.05. In the event that no commercial transaction is carried out, the Company
must nevertheless send Normandy University via Normandie Valorisation, acting on behalf of the Establishments, a statement certifying the absence of any operation during the year in question to the address indicated in Section 6.01 of this
Agreement, indicating the causes of the absence of sales and the difficulties encountered. 
 Section 6.06. The sums received by
Normandy University via Normandie Valorisation, on behalf of the Establishments, by virtue of this Agreement remain in any event definitively and irremediably acquired and may under no circumstances be returned to the Company. In addition, any sums
that remain due from the Company to Normandy University via Normandie Valorisation, on behalf of the Establishments, upon the expiry or termination date of this Agreement, must be paid to Normandy University via Normandie Valorisation, on behalf of
the Establishments. 
 Section 6.07. The sums due by the Company to Normandy University via Normandie Valorisation, on behalf of the
Establishments, will be increased by the legal taxes in force, in particular by VAT if applicable. 
 ARTICLE 7 

SECRET 

Section 7.01. Each of the Parties undertakes to keep the Confidential Information secret for the duration of the Agreement and for a
period of [**] after its termination or expiry. 
 Each Party undertakes not to protect in the Field of Use, in any way whatsoever, all or
part of the Confidential Information transmitted by the other Party, in particular by filing a patent application, and not to use them for any purpose other than those set out in Article 1, without the prior written consent of the latter. 

The Parties will ensure that their personnel and any person attached to their service in any capacity whatsoever are also be bound by this
duty of confidentiality. 

  
 10 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 The Parties hereby agree that any disclosure by the Company to a third party of any
Confidential Information related to the invention protected by the Patent will be preceded by the signing of a confidentiality agreement with similar terms and conditions to those of this Article. 

The confidentiality agreements to which the PARTIES are bound pursuant to this Article shall not apply to information for which the receiving
Party can prove: 
 (a) that it was disclosed to them by mutual agreement between the Parties, or that the disclosure was previously made by
the Owning Party; 
 (b) that it was already in the public domain at the time it was communicated by the other Party or the Co-Owner, or that it entered the public domain after this communication through no fault of the recipient Party; 

(c) that they were lawfully received from a third party without breaching the confidentiality obligations contained in this article; 

(d) that, on the date of their communication by the owning Party, they were already in its possession; 

(e) that their disclosure has been imposed by the application of a mandatory legal or regulatory provision or by the application of a final
court decision or an arbitration award. 
 Section 7.02. This article cannot prevent the Company from sharing documents for the purpose
of promoting the marketing of the Products in compliance with the conditions set out in this Agreement. 
 ARTICLE 8 

FILING, EXTENSION, ISSUE AND MAINTENANCE IN
FORCE OF THE PATENTS 
 Section 8.01. Normandy University via its component
Normandie Valorisation, on behalf of the Establishments, is responsible for the management of the files, including the follow-up of procedures for the issue and maintenance in force and defence of the Patent,
in collaboration with the Establishments. 
 Section 8.02. Normandy University via its Normandie Valorisation component shall be liable
on behalf of Establishments, to pay any costs relating to the procedures for obtaining, examining, extending, maintaining in force and defending the Patent in those countries of the Territory where they have been filed or granted, throughout the
duration of the Agreement. 

  
 11 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 ARTICLE 9 

GUARANTEES 

Section 9.01. The Establishments guarantee the material existence of the Patent and that they are entitled to enter into this Licence
agreement. 
 The Establishments do not give any express or implicit guarantee regarding the suitability of the Patent to achieve any result
whatsoever. 
 The Establishments do not guarantee the granting of Patents that are still under examination but shall inform the Company of
any adverse development to their being granted. 
 [**] 

Section 9.02. The Company may not call upon the Establishments as security in the event of damages of any kind whatsoever caused by the
Products, the Company being held solely responsible towards its customers and/or any third party for the quality and performance of Products. 

Section 9.03. The Company is solely responsible for ensuring that the Products comply with the applicable laws and regulations. 

Section 9.04. Notwithstanding any provision of this Agreement to the contrary, the Establishments shall not grant third parties access to
the Patents in the Field of Use without the prior written consent of the Company, and shall preserve their exclusivity, as understood in this Agreement. Similarly, the Establishments undertake to disclose to the Company the existence of any licence
relating to Patents conferred by the Establishments on third parties prior to the entry into force of this Agreement. For the sake of clarity, it is understood that the Partners must obtain the written consent of the Company if they wish to exploit,
develop or otherwise use the Patent in the Field of Use, with the exception of the case provided for in Section 1.01 of this Agreement. 

Section 9.05. The stipulations of Article 9 shall remain in force notwithstanding the early termination or expiry of this Agreement. 

ARTICLE 10 

TERMINATION – EXPIRY 

Section 10.01. In the event that the Company ceases all activity, is dissolved, or is subject to amicable or judicial liquidation
proceedings, this Agreement will be automatically terminated. In the event that the Company is the subject of judicial redress proceedings, Normandy University via Normandie Valorisation, acting on behalf of the Establishments, may terminate this
Agreement subject to notifying the Company by registered letter with acknowledgement of receipt. If no response is received within [**] of said notification, this Agreement will be automatically terminated. 

  
 12 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Section 10.02. This Agreement may be automatically terminated by one of the Parties in
the event of non-fulfilment by the other Party of one or more of the obligations contained in its various clauses, and in particular in Article 5 and/or 6. This termination will only become effective three
(3) months after the complainant Party has sent a registered letter with acknowledgement of receipt setting out the reasons for the request, unless, within this period, the defaulting Party has fulfilled its obligations or has provided proof of
an impediment resulting from a case of force majeure. The exercise of this right to terminate does not exempt the defaulting Party from fulfilling its contractual obligations until the effective date of the termination, without prejudice to the
payment for damages owed by the defaulting Party in compensation for any damage suffered by the complainant Party as a result of the early termination of this Agreement. 

Section 10.03. This Agreement will also be automatically terminated if the Patent is invalidated in France. 

Section 10.04. If the Company disputes the validity of the Patents or supports Third Parties to contest the patentability or validity of
the rights of the Patents, Normandy University via Normandie Valorisation, acting on behalf of the Establishments, may terminate this Agreement immediately. 

Section 10.05. If this Agreement is terminated, the Company shall no longer directly or indirectly use the Patents resulting from patent
applications no. [**] and no. [**] until their expiry. Nothing in this article could prevent the Company from continuing to use the Patents to the extent that they are integrated into Products or services already existing at the moment of the
termination. The terms and conditions of this licence will continue to apply to such products. 
 Section 10.06. In the event of
termination, the Establishments will be free to grant all of the rights they hold relating to the Patent to any Third Party, without any obligation towards the Company. 

ARTICLE 11 
 STOCKS

 If the Company and/or its Affiliates have Products in stock on the Agreement termination date, they would be authorized to sell these
fully-manufactured Products in the Territory for a period of [**] following the date of termination and/or expiry of the Agreement, subject, on the one hand, to sending a written inventory of stocks to Normandy University via Normandie Valorisation,
acting on behalf of the Establishments, on the Agreement termination date and, on the other hand, to respecting the provisions of Article 6 of this Agreement (Financial conditions). After said period of [**], the Company and/or its Affiliates and/or
its distributors and/or its Sub-Licensees will no longer be entitled to sell any Product. 

  
 13 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 ARTICLE 12 

INFRINGEMENT 

Section 12.01. Normandy University via Normandie Valorisation, on behalf of the Establishments and the Company, will inform each other
[**] of any case of infringement by a third party in relation to the Patent of which they are aware and/or any claim or infringement action against them. 

Section 12.02. In the event of an infringement of one or more Patents in the Field of Use by a third party, the Establishments may
initiate legal proceedings against the infringing third party at their own expense; it being understood that the compensation and any damages awarded by the court will be fully and irrevocably acquired. 

This provision shall not prevent the Company from intervening in the proceeding, at its own expense, to obtain compensation for its own
specific damages. SOPHiA GENETICS shall have full and irrevocable entitlement to any compensation and damages awarded to it as a result of such proceedings. 

If the Establishments decide not to initiate any infringement actions and if the Company wishes to act, the Company may, after a formal notice
sent by registered letter with acknowledgement of receipt to Normandy University via Normandie Valorisation on behalf of the Establishments has remained unanswered by the Establishments for more than [**], start a proceeding for infringement at its
sole initiative, in its sole name and at its own expense. In countries where a legal provision prohibits it from initiating a proceeding, the Establishments shall provide, at the Company’s simple request and in a timely manner, all the powers
that are necessary for it to act in the name and stead of the Establishments. 
 Section 12.03. If infringement proceedings are brought
against the Company and/or its Affiliates when it comes to using the Products, due to the use of Patents in the Field, Normandy University via Normandie Valorisation, acting on behalf of UNIROUEN and CHB, will make its best efforts to help the
Company defend its interests and those of its Affiliates. 
 [**]. 

[**]. 
 [**]. 

Section 12.04. If the Patent is cancelled, the provisions relating to guarantees shall apply and may not be waived. 

  
 14 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Section 12.05. The Parties agree to provide each other with all of the documents and
elements they may need during the aforementioned procedures. 
 ARTICLE 13 

ENTIRE AGREEMENT AND LIMITS OF THE
AGREEMENT 
 Section 13.01. This Agreement expresses the entire agreement between the Parties relating to its subject
matter and replaces and cancels all previous verbal or written agreements relating to said subject matter. No general or specific condition appearing in the documents sent or submitted by the Parties may be incorporated into this Agreement. 

Section 13.02. This Agreement may only be modified or renewed by an addendum signed by the representatives of the Parties, duly
authorised for this purpose. 
 Section 13.03. It is hereby specified that the relations established between the Parties under this
Agreement do not confer any rights other than those mentioned in this Agreement. It is understood that this Agreement does not entail, in particular, the granting to the Company of any right on Patents outside the Field and the Territory. 

Section 13.04. The Agreement must under no circumstances be interpreted as creating a relationship of association or a de facto
partnership between the Parties, each of them being considered as an independent co-contractor. 

Section 13.05. Any public declaration or communication relating to the signing of the Agreement or its content can only be made with the
agreement of the Parties. However, it is agreed that the Company may register the Agreement with the patent offices as stipulated in Article 18 below. 

ARTICLE 14 

HEADINGS 
 In the
event of any difficulties of interpretation between any clause heading and any of the clauses, the headings will be deemed non-existent. 

ARTICLE 15 

INVALIDITY OF A CLAUSE 

If one or more of the provisions of this Agreement are deemed to be invalid or declared as such in application of a law or regulation –
and in particular, European Union law – or following a final decision by a competent court, the other provisions shall remain valid and enforceable and the Parties shall immediately proceed to make the necessary modifications, respecting, as
far as possible, the intent that existed on the date of signing this Agreement. 

  
 15 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 ARTICLE 16 

WAIVER 
 The fact
that one Party does not pursue a breach of any of the obligations under this Agreement by the other Party cannot be interpreted in the future as a waiver of the obligation concerned. 

ARTICLE 17 

DISPUTES – APPLICABLE LAW 

Section 17.01. This Agreement is governed by French laws and regulations. 

Section 17.02. In the event of difficulty regarding the validity, interpretation or performance of this Agreement, the Parties shall
endeavour to resolve their dispute amicably. 
 Section 17.03. In the event of a persistent disagreement, lasting more than [**], from
the first notification concerning the dispute, the dispute will be brought before the competent Courts. 
 Section 17.04. This Article
will remain in force notwithstanding all cases of expiry or termination of this Agreement. 
 ARTICLE 18 

REGISTRATION IN THE NATIONAL PATENT REGISTER 

Section 18.01. This Agreement may be entered in the National Patent Register, kept by the National Institute of Industrial Property, and
in the national patent registers, kept by national Industrial Property offices, for the purposes of registering Patents, at the expense of the Company. 

Section 18.02. Any necessary tax registration of this Agreement will be carried out by the Company at its sole expense. 

ARTICLE 19 

NOTIFICATIONS 
 Any
communication or notification under this Agreement must be made by fax or registered mail with acknowledgement of receipt, to the Party concerned at the following address, as long as a change of address has not been notified in writing: 

On behalf of the Establishments: 

  
 16 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 [**] 

[**] 
 [**] 

[**] 
 [**] 

On behalf of the Company: 
 [**]

 [**] 
 [**] 

  
 17 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 Issued in six (6) original copies. 

 

							
	 On behalf of the COMPANY 

  

[**] 14/03/2018 
On 14.03.2018
	  	 On behalf of NORMANDY UNIVERSITY 

  

[**] 
On 19.03.2018

				
	By:	  	 /s/ on behalf of SOPHiA

GENETICS SA
	  	By:	  	 /s/ on behalf of Normandy

University

		  	Name: [**]	  		  	Name: [**]
		  	Title:   [**] 
	  		  	Title:   [**]

  

			
	By:	 	 /s/ on behalf of SOPHiA

GENETICS SA

		 	Name: [**]
		 	Title:   [**]

  

									
		 		  		  	 Approved by NORMANDIE VALORISATION 

  

[**]

					
		 		  		  	By:	  	 /s/ on behalf of Normandie

Valorisation

		 		  		  		  	Name: [**]
		 		  		  		  	Title:   [**]

 [Signature Page to Exclusive License Agreement] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 













 APPENDIX 1: STATEMENT OF ITEMS PROVIDED BEFORE THE LICENSE 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 













 APPENDIX 2: STATEMENT OF PATENTS ON THE EFFECTIVE DATE 

[**] 

  
 20 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 APPENDIX 3: DEVELOPMENT PLAN 

Non-binding Product Development Plan* 

[**] 

  
 21 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has
determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 













 APPENDIX 4: LIST OF AFFILIATES 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential.